S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
Top-Rated Stocks  
NASDAQ:RCKT

Rocket Pharmaceuticals - RCKT Stock Forecast, Price & News

$22.23
-0.16 (-0.71%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$21.54
▼
$22.73
50-Day Range
$17.06
▼
$22.76
52-Week Range
$7.57
▼
$23.48
Volume
607,880 shs
Average Volume
731,637 shs
Market Capitalization
$1.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.45

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
140.5% Upside
$53.45 Price Target
Short Interest
Bearish
9.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.12mentions of Rocket Pharmaceuticals in the last 14 days
Based on 34 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.02) to ($3.01) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

130th out of 1,055 stocks

Pharmaceutical Preparations Industry

51st out of 519 stocks

See Top Rated MarketRank™ Stocks Here

RCKT stock logo

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Stock News Headlines

January 12, 2023 | marketbeat.com
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023 (RCKT)
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.
January 28, 2023 | finance.yahoo.com
12 Cash-Rich Small Cap Stocks To Invest In
January 28, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
January 27, 2023 | americanbankingnews.com
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Expected to Earn FY2022 Earnings of ($3.26) Per Share
January 25, 2023 | msn.com
Rewatch Space Startup Rocket Lab's First Launch From the US
January 25, 2023 | msn.com
Rocket Lab aces its first launch from U.S. soil
January 25, 2023 | americanbankingnews.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 2.4% Following Analyst Downgrade
January 25, 2023 | americanbankingnews.com
Rocket Pharmaceuticals (NASDAQ:RCKT) PT Lowered to $49.00
January 28, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
January 24, 2023 | msn.com
Rocket Lab launches 1st Electron booster from US soil in twilight liftoff
January 24, 2023 | msn.com
Rocket Lab launches 3 satellites in first mission from U.S. soil
January 24, 2023 | msn.com
Watch live as Rocket Lab launches its first rocket from the US
January 24, 2023 | techcrunch.com
Watch Rocket Lab launch Electron from US soil for the first time
January 24, 2023 | msn.com
Rocket Lab's First Launch From the US Could Be Visible to Millions Tonight
January 24, 2023 | msn.com
Pompeo says Trump had to explain 'Rocket Man' joke to Kim Jong Un: Book
January 24, 2023 | msn.com
Watch live: Rocket Lab's big Electron launch from Wallops set for tonight
January 24, 2023 | msn.com
Watch Rocket Lab launch Electron from U.S. soil for the first time
January 24, 2023 | americanbankingnews.com
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Expected to Post Q1 2023 Earnings of ($0.79) Per Share
January 23, 2023 | msn.com
Trump had to explain his 'Little Rocket Man' nickname to Kim Jong Un, Mike Pompeo says in new book
January 23, 2023 | msn.com
Rocket Lab now targeting Jan. 24 for 1st-ever launch from US. Here's how to watch live.
January 23, 2023 | msn.com
The Latest Analyst Ratings for Rocket Pharmaceuticals
January 23, 2023 | msn.com
Weather again plays spoiler for Rocket Lab's first Electron launch from Wallops
January 23, 2023 | msn.com
POSTPONED: Rocket launch from Wallop's rescheduled for Tuesday evening should be visible in our area
January 23, 2023 | markets.businessinsider.com
SVB Securities Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
January 23, 2023 | msn.com
Wall Street Analysts Think Rocket Pharmaceuticals (RCKT) Could Surge 163.35%: Read This Before Placing a Bet
January 23, 2023 | nasdaq.com
Rocket Pharmaceuticals (RCKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
January 22, 2023 | msn.com
Here's When NASA Rocket Launch Will Be Visible Across East Coast
See More Headlines
Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Company Calendar

Last Earnings
11/03/2022
Today
1/28/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RCKT
CUSIP
N/A
CIK
1281895
Web
www.rocketpharma.com
Phone
(609) 659-8001
Fax
646-224-9585
Employees
151
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$53.45
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+140.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-169,070,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-49.01%
Return on Assets
-44.15%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
10.31
Quick Ratio
10.31

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.05 per share
Price / Book
3.15

Miscellaneous

Outstanding Shares
75,680,000
Free Float
50,201,000
Market Cap
$1.68 billion
Optionable
Optionable
Beta
1.43

Key Executives

  • Gaurav D. ShahGaurav D. Shah
    Chief Executive Officer & Director
  • Kinnari Patel
    President & Chief Operating Officer
  • John C. Militello
    Treasurer, Chief Financial & Accounting Officer
  • Jonathan David Schwartz
    Chief Medical Officer & SVP-Clinical Development
  • Mayo Pujols
    Chief Technical Officer & Executive Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RCKT Stock - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price forecast for 2023?

11 equities research analysts have issued 12-month target prices for Rocket Pharmaceuticals' shares. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they anticipate the company's share price to reach $53.45 in the next twelve months. This suggests a possible upside of 140.5% from the stock's current price.
View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts.

How have RCKT shares performed in 2023?

Rocket Pharmaceuticals' stock was trading at $19.57 at the beginning of 2023. Since then, RCKT stock has increased by 13.6% and is now trading at $22.23.
View the best growth stocks for 2023 here.

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our RCKT earnings forecast.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings data on Thursday, November, 3rd. The biotechnology company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.77) by $0.10.

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (1.33%), Comerica Bank (0.38%), Hennion & Walsh Asset Management Inc. (0.13%), Harbor Capital Advisors Inc. (0.09%) and Clear Harbor Asset Management LLC (0.01%). Insiders that own company stock include Gaurav Shah, Gotham Makker, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $22.23.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.68 billion. The biotechnology company earns $-169,070,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

The company employs 151 workers across the globe.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 1/28/2023 by MarketBeat.com Staff